On November 12, 2025 Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), reported that data from multiple pipeline programs, including long-term and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option, will be presented during the CTOS Annual Meeting 2025, taking place November 12-15 in Boca Raton, Florida.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited about the breadth of data we’re presenting at CTOS this year, which underscore the strong progress we continue to sustain across our pipeline," said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. "We look forward to sharing encore data from our Phase 3 MOTION study of vimseltinib and providing updates on our DCC-3009 Phase 1 program, which demonstrate how we can expand our GIST treatment capabilities by targeting known primary and secondary drug-resistant mutations spanning multiple KIT exons."
Oral and Poster presentation details are as follows:
Title: Long-Term Efficacy and Safety of Vimseltinib in Patients (Pts) with Tenosynovial Giant Cell Tumor (TGCT): Results from the MOTION Phase 3 Trial
Presenter: Silvia Stacchiotti, M.D., Fondazione IRCCS Istituto Nazionale Dei Tumori
Session Title: Session 8: TGCT & Desmoid Tumor
Session Date: Friday, November 14, 2025
Session Time: 2:30 – 3:30 PM ET
Title: Impact of Expert-Led Education Programs on Health Care Provider (HCP) Knowledge of Gastrointestinal Stromal Tumor (GIST)
Presenter: Mark Agulnik, M.D., USC Norris Comprehensive Cancer Center, University of Southern California
Poster Reception: Thursday, November 13, 2025
Session Time: 5:30 – 6:30 PM ET
Title: Efficacy with Vimseltinib in Patients (Pts) with Tenosynovial Giant Cell Tumor (TGCT) and Prior Colony-Stimulating Factor 1 (CSF1) Inhibitor Therapy: A Phase 2 Case Series
Presenter: Andrew J. Wagner, M.D., Ph.D., Harvard Medical School, Dana-Farber Cancer Institute
Poster Reception: Thursday, November 13, 2025
Session Time: 5:30 – 6:30 PM ET
Title: Effect of a High-Fat Meal on the Pharmacokinetics (PK) of Vimseltinib, an Oral Inhibitor of the Colony-Stimulating Factor 1 Receptor (CSF1), in Healthy Participants
Presenter: Chengyue Zhang, Ph.D., Deciphera Pharmaceuticals, LLC
Poster Reception: Thursday, November 13, 2025
Session Time: 5:30 – 6:30 PM ET
Title: Effect of Itraconazole (ITX) and Rabeprazole (RBP) on the Pharmacokinetics (PK) of Vimseltinib, an Oral Inhibitor of the Colony-Stimulating Factor 1 Receptor (CSF1), in Healthy Participants
Presenter: Chengyue Zhang, Ph.D., Deciphera Pharmaceuticals, LLC
Poster Reception: Thursday, November 13, 2025
Session Time: 5:30 – 6:30 PM ET
Title: An Open-Label Phase 1/2 Study of DCC-3009 Monotherapy in Patients (Pts) with Advanced Gastrointestinal Stromal Tumor (GIST)
Presenter: Suzanne George, M.D., Division of Sarcoma, Dana-Farber Cancer Institute – Sarcoma Center
Poster Reception: Thursday, November 13, 2025
Session Time: 5:30 – 6:30 PM ET